Avina K. Singh

Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

Tait D. Shanafelt, Xin V. Wang, Neil E. Kay et al. · New England Journal of Medicine · 2019 · 738 citations · Full text

Medicine, Immunology, Oncology +16

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen et al. · The Lancet Oncology · 2020 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson et al. · Blood · 2022 · 237 citations · Full text

Medicine, Immunology, Pharmacotherapy +13

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino et al. · New England Journal of Medicine · 2024 · 200 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Tait D. Shanafelt, Victoria Wang, Neil E. Kay et al. · Blood · 2019 · 36 citations

Medicine, Immunology, Oncology +8